ReviewVaccines2020
Efforts at COVID-19 Vaccine Development: Challenges and Successes.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- COVID Diaries, State Response to COVID Vaccination Program, December 2020 to September 2021.Scientific data · 2026Article
- Determination of Factors Affecting Covid-19 Vaccine Literacy and in Pandemics Vaccine Hesitation Levels of Adults: A Cross-sectional Study.Malawi medical journal : the journal of Medical Association of Malawi · 2025Article
- Next-Generation Nucleic Acid-Based Diagnostics for Viral Pathogens: Lessons Learned from the SARS-CoV-2 Pandemic.Microorganisms · 2025Review
- Development of a Peptide-Based Multiepitope Vaccine from the SARS-CoV-2 Spike Protein for Targeted Immune Response Against COVID-19.Protein and peptide letters · 2025Article
- Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine.European journal of microbiology & immunology · 2024Article
- Parents' views on pediatric COVID-19 vaccine in Saudi Arabia.Journal of family medicine and primary care · 2024Article
- Comparison of RT-PCR cycle threshold values between individual and pooled SARS-CoV-2 infected nasopharyngeal swab specimens.Narra J · 2024Article
- Clinical Research into Central Nervous System Inflammatory Demyelinating Diseases Related to COVID-19 Vaccines.Diseases (Basel, Switzerland) · 2024Article
- Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection.Journal of Taibah University Medical Sciences · 2023Review
- A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations.Vaccines · 2023Review
- Designing an optimization model for the vaccine supply chain during the COVID-19 pandemic.Expert systems with applications · 2023Article
- BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy.Vaccines · 2023Article
- Mathematical Modeling of SARS-CoV-2 Omicron Wave under Vaccination Effects.Computation (Basel, Switzerland) · 2023Article
- Intervention Analysis of COVID-19 Vaccination in Nigeria: The Naive Solution Versus Interrupted Time Series.Annals of data science · 2023Review
- Identifying factors influencing COVID-19 vaccine uptake in Finland - a qualitative study using social media data.Frontiers in public health · 2023Article
- Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward.Human vaccines & immunotherapeutics · 2022Article
- Awareness and acceptance of COVID-19 vaccines and associated factors among pharmacy students in Zambia.Malawi medical journal : the journal of Medical Association of Malawi · 2022Article
- Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.Inflammopharmacology · 2022Review
- Attitude towards COVID-19 vaccination among healthcare workers: a cross sectional study from Egypt.BMC health services research · 2022Article
- Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine.Vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid spread of SARS-CoV-2, the new coronavirus (CoV), throughout the globe poses a daunting public health emergency. Different preventive efforts have been undertaken in response to this global health predicament; amongst them, vaccine development is at the forefront. Several sophisticated designs have been applied to create a vaccine against SARS-CoV-2, and 44 candidates have already entered clinical trials. At present, it is unclear which ones will meet the objectives of efficiency and safety, though several vaccines are gearing up to obtain emergency approval in the U.S. and Europe. This manuscript discusses the advantages and disadvantages of various vaccine platforms and evaluates the safety and efficacy of vaccines in advance stages. Once a vaccine is developed, the next challenge will be acquisition, deployment, and uptake. The present manuscript describes these challenges in detail and proposes solutions to the vast array of translational challenges. It is evident from the epidemiology of SARS-CoV-2 that the virus will remain a threat to everybody as long as the virus is still circulating in a few. We need affordable vaccines that are produced in sufficient quantity for use in every corner of the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.